Why the study?
Catheter ablation is rarely used for arrhythmias during pregnancy, and zero-fluoroscopic catheter ablation may be preferable to medical treatment.
Does zero-fluoroscopic catheter ablation safely and effectively treat arrhythmias in pregnant women?
Does zero-fluoroscopic catheter ablation safely and effectively treat arrhythmias in pregnant women?
Zero-fluoroscopic catheter ablation is a safe and effective treatment for maternal arrhythmias during pregnancy, avoiding radiation exposure and potentially reducing fetal side effects compared to medical therapy.
Supports zero-fluoroscopic ablation feasibility in pregnancy; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Catheter ablation is a rarely used procedure to treat arrhythmias during pregnancy. HYPOTHESIS: In the case of maternal arrhythmia during pregnancy, zero-fluoroscopic catheter ablation is preferable to medical treatment. METHODS: Between April 2014 and September 2021, we examined the demographic data, procedural parameters, and fetal and maternal outcomes in pregnant women undergoing ablation at the Gottsegen National Cardiovascular Center and University of Pécs Medical School, Heart Institute. RESULTS: Fourteen procedures (14 electrophysiological studies [EPS], 13 ablations) performed on 13 pregnant women (age 30.3 ± 5.2 years, primipara n = 6) were studied. During EPS, 12 patients had inducible arrhythmias. Atrial tachycardia was confirmed in three, atrioventricular re-entry tachycardia via manifest accessory pathway (AP) in three, and via concealed AP in one case. Atrioventricular nodal re-entry tachycardia was confirmed in three and sustained monomorphic ventricular tachycardia in two cases. Eleven radiofrequency ablation (84.6%) and two cryoablation (15.4%) were performed. The electroanatomical mapping system was used in all cases. Transseptal puncture was performed in two cases (15.4%) due to left lateral APs. The mean procedure time was 76.0±33.0 minutes. All procedures were performed without fluoroscopy. No complications occurred. During the follow-up, arrhythmia-free survival was achieved in all cases, but in two patients, we used antiarrhythmic drugs (AADs) to achieve it. APGAR score was within the normal range in all cases [median (interquartile range), 9.0/10.0 (9.0-10.0/9.3-10.0)]. CONCLUSIONS: Zero-fluoroscopic catheter ablation was an effective and safe treatment option for our 13 pregnant patients. Catheter ablation may have less side effects on fetal development than the use of AADs during pregnancy.
No takes yet. Share an insight, caveat, or question.
Mladoniczky et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: